towards the utilization of cannabinoids as anti-cancer...
TRANSCRIPT
Towards the utilization of cannabinoids as anti-cancer
agentsagents
Guillermo Velasco
Sestri Levante September 2015
Anti-cancer activity of cannabinoids
Munson Munson et al.et al. (1975) (1975) Antineoplastic activity of cannabinoidsAntineoplastic activity of cannabinoidsJ. Natl. Cancer Inst. 55, 597J. Natl. Cancer Inst. 55, 597--602602J. Natl. Cancer Inst. 55, 597J. Natl. Cancer Inst. 55, 597 602602
Cannabinoids exhibit anti-tumor activity in many differentanimal models of cancer
Glioma
animal models of cancer
MelanomaSkin carcinomaSkin carcinoma Lung cancer
Hepatocellular carcinomaBreast cancer
Pancreatic adenocarcinoma
Prostate cancer
Leukaemia
Selectivity of cannabinoid anticancer action
Veh Cannabinoid
PancreasVeh Cannabinoid
s
TP PP
Nuc
leos
Normal cell Tumor cell T
TP P P
Normal cell Tumor cell
TUN
ELSupervival
T
Carracedo et al. Cancer Res (2006)
A 1st Pilot Clinical trialA 1st Pilot Clinical trial (2003-2006)
Glioblastoma (GBM)
GBMdiagnosis
(n=9)
Infusion catheter(Pre-treatmenttumour biopsy)( )
1st Surgery Radiotherapy±Chemotherapy
Relapse
p y)
THC treatmentPost-treatmenttumour biopsy Decease
EXPERIMENTAL PERIOD SURVIVAL
THC activates the autophagy-mediated cell deathpath a in h man glioblastoma samples
Cell proliferation (Ki67) Angiogenesis (CD31)
pathway in human glioblastoma samples
Pre-THC Post-THCPost-THCPre-THC
Apoptosis (caspase 3)Autophagy (LC3) Apoptosis (caspase 3)Autophagy (LC3)
Pre-THC Post-THC Pre-THC Post-THC
Survival of patientsp
n
1.0
0 5 frac
tion
Median survival = 24 wk(95% CI: 15-33)
Si il h d ( TMZ)0.5
urvi
ving
Similar to other drugs (e.g. TMZ)
0
Su
0
Time after THC (wk)
0 20 40 60
Strategies aimed at optimisingStrategies aimed at optimising cannabinoid anticancer activity
1) Increasing our knowledge on the molecular mechanisms1) Increasing our knowledge on the molecular mechanisms involved in cannabinoid anticancer action
2) Identifying the molecular factors associated with cell resistance to cannabinoid anticancer action
3) Designing the most appropriate cannabinoid-based combinational therapiescombinational therapies
CBD and other phytocannabinoids
?CBD
TRPVsOth t ?
CB1, CB2
ROS
Other receptors?
ROSAdditional mechanisms
AutophagyApoptosis Cancer cell deathApoptosis Cancer cell death
Strategies aimed at optimisingStrategies aimed at optimising cannabinoid anticancer activity
1) Increasing our knowledge on the molecular mechanisms1) Increasing our knowledge on the molecular mechanisms involved in cannabinoid anticancer action
2) Identifying the molecular factors associated with cell resistance to cannabinoid anticancer action
3) Designing the most appropriate cannabinoid-based combinational therapiescombinational therapies
Predictor of resistance to cannabinoid ti ti itanticancer activity
Primary cultures of human glioma cells
**THC 6 μM
100120140160
from
Veh
icle
)
ALDH2IGFBP5MDKve
ls (a
.u.)
0.5
1
020406080
100
ell v
iabi
lity
(%
PDGFRACSF1GBP2UPP1ID3m
RN
A le
v
PDGFRA
CSF1
GBP2
UPP1
ID3
0
0
Ce
ALDH2
IGFBP5
MDK
Strategies aimed at optimisingStrategies aimed at optimising cannabinoid anticancer activity
1) Increasing our knowledge on the molecular mechanisms involved in cannabinoid anticancer action
2) Identifying the molecular factors associated with cell2) Identifying the molecular factors associated with cell resistance to cannabinoid anticancer action
3) Designing the most appropriate cannabinoid-based combinational therapies
Standard GBM therapyGBM
diagnosisSurgery Radiotherapy
TMZ
Relapse2nd line
therapies+TMZ?
TMZ Decease
NEWLY-DIAGNOSED GBM RECURRENT GBM
GBM
Cannabinoids enhance TMZ anticancer activity inGBM li i l d lGBM preclinical models
U87 MG astrocytoma cells
8
10
VEH
y 1)
U87MGVeh
U87 MG astrocytoma cells
M ± S E M
THC+TMZ
4
6
THC 15 mg/KgTMZ 5 mg/Kg
olum
e (%
day
THC
Mean ± S.E.MVehicle 9.2±0.6THC 5.1±0.4
TMZ 3.2±0.4,
****
2
4
Tum
or v
o
TMZTMZ 3.2±0.4
TMZ+THC 0.4±0.0## ΩΩ**
01 3 5 7 9 11 13 15
Days of treatment
THC+TMZ
Similar effect on cannabinoid and TMZ-resistant tumors
Selecting the appropriate cannabinoids for anticancer therapies
- CBD has anticancer activity by itself
THC CBD
CB1/CB2 agonists ?
+ (1:1) - CBD attenuates the psychoactive effects of THC
- Wide experience in the use THC and CBD (Sativex) CB1/CB2 agonists ?
FAAH/MAGL inhibitors?
p ( )
Other phytocannabinoids?
Cannabinoids enhance TMZ anticancer activity
U87 MG astrocytoma cells
12VEH
SAT (7 5 /k THC BDS 7 5 /k CBD BDS))
Peritumoral administration
8
10SAT (7.5 mg/kg THC-BDS + 7,5 mg/kg CBD-BDS)
TMZ (5 mg/kg)
SAT + TMZ
THC (15 mg/kg) Mean ± S.E.M
VEH 10.3 ± 0.4
SAT 6.2 ± 0.3 ∗∗
d fr
om d
ay 1
)
6
THC (15 mg/kg) + TMZ THC (15 mg/kg) 5.8 ± 0.5
TMZ (5 mg/kg) 4.1 ± 0.4
SAT ∗∗
∗∗
SAT + TMZ 2.6 ± 0.3∗∗ΣΣ ΩΩ
volu
me
(fold
2
4THC + TMZ 2.4 ± 0.3
SAT TMZ 2.6 ± 0.3##∗∗ ΩΩ
Tum
or v
0 2 4 6 8 10 12 14 16
0
Time ( days)Time ( days)
Cannabinoids + temozolomide therapy for GBM patientsCannabinoids temozolomide therapy for GBM patients
Second line study (started)
GBMdiagnosis Relapse Sativex
y ( )
diagnosisSurgery Radiotherapy
+TMZ?TMZ
p
Decease
Sativex+ TMZ
NEWLY-DIAGNOSED GBM RECURRENT GBMRelapse
Do MK levels predict resistance to Sativex + TMZ therapy?
Clinical Trial (ongoing) Primary objectivesTo determine the safety profile of- To determine the safety profile of
Sativex® in combination with TMZ- To provide preliminary evidence of anti-tumoural activity for this drug combinationtumoural activity for this drug combination(comparison with a high-dense regime of temozolomide)
Other clinical studies with CBs as anti-cancer agentsOther clinical studies with CBs as anti cancer agents
Selecting the appropriate cannabinoids for anticancer therapies
THC CBD+(1:1)Other ratios THC:CBD
CB1/CB2 agonists ?
FAAH/MAGL inhibitors?
Optimizing delivery methods/via of administration
FAAH/MAGL inhibitors?
Other phytocannabinoids?
Marijuana Sativex(THC/CBD)
Marinol(THC)
Cesamet(Nabilone)
Which cancer types?
Glioma
Cancer types lacking effective treatments
Melanoma
Pancreatic adenocarcinoma
Which cancer types?Subtypes of cancer that do not respond to current therapies
Breast cancer
Prostate cancer
Combinational therapies?
CombinationalCBs + Classic anticancer treatments (ChT and RT)
Combinational therapies
CBs + Targeted therapies
CBs + Classic anticancer treatments (ChT and RT)+ Targeted therapies
Additional preclinical research is still required
Future of cancer treatment: individualized therapies
THC 6 μM**
140160
m V
ehic
le)
THC 6 μM
ALDH2s (a
.u.) 1
20406080
100120
iabi
lity
(% fr
om IGFBP5MDKPDGFRACSF1GBP2UPP1m
RN
A le
vels
CSF1
GBP2
UPP1
ID3
0
0.5
020
Cel
l vi
ID3mALDH2
IGFBP5
MDK
PDGFRA
CSF1
It is essential to identify the molecular factors associated with the resistance/sensitivity to cannabinoid anticancer action in clinical studiesresistance/sensitivity to cannabinoid anticancer action in clinical studies
U624 INSERM (Marsella)
AcknowledgementsHospital 12 de Octubre U624 INSERM (Marsella)
J.L. Iovanna
Manuel Guzmán CIB (Madrid)Patricia BoyaHospital Clínico San Carlos
Hospital 12 de Octubre(Madrid)
Juan SepúlvedaAurelio Hernández Laín
David Dávilay
IRCCS 'L. Spallanzani‘(Roma)
Mauro PiacentiniFrancesco Cecconi
Hospital Clínico San Carlos(Madrid)
Juan BarciaPedro Pérez Segura
Eva Resel
Elena G Taboada
Mar Lorente
Israel López Valero
José González Francesco CecconiHospital Virgen de la Salud
(Toledo)Bárbara MeléndezManuela Mollejo
María Salazar
Sonia HernándezCristina Sánchez
U Sheffield (Sheffield, UK)E. Kiss-Toth
f
Alba Orea Ismael Galve-Roperh
Hospital Universitario(Tenerife)
L González-FeriaSofía Torres
María Salazar
Fátima Rodríguez
Iñi S l
Center for Cancer Research(Copenhagen)
M, Jaattela
U Newcastle (Newcastle UK)
Arkaitz Carracedo
MRC PPU (Dundee)Dario Alessi
Iñigo Salanueva
Ainara Egia
U. Newcastle (Newcastle, UK)P. Lovat
ISCiii (Madrid)Pilar Sánchez
Dario Alessi
CSIC(Barcelona)
G Fabrias
UPV(Bilbao)F Goñi
J Casas A AlonsoR Montes